StockData
QuidelOrtho Corp logo

QuidelOrtho Corp (QDEL) stock

QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.87−0.34 (-3.33%)

Close on Nov 17, 2026Market cap $676.84MP/E –Yield –

QuidelOrtho r&d expenses

Research and development expenses are spending on new products and technology.

QuidelOrtho's R&D Expenses for the twelve months ending Sep 27, 2026 was $181.90M, down 3.1% year over year. For fiscal 2025 it was $186.20M, down 14.9% from the year before. The highest annual figure on record is $245.00M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 28, 2025$186.20M-14.9%
FY2024Dec 29, 2024$218.70M-10.7%
FY2023Dec 31, 2023$245.00M+30.4%
FY2022Jan 1, 2023$187.90M+96.3%
FY2021Jan 2, 2022$95.70M+13.5%
FY2020Jan 3, 2021$84.30M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 27, 2026$42.50M+2.4%
Q2 FY2026Jun 28, 2026$48.70M+6.6%
Q1 FY2026Mar 29, 2026$44.90M-15.6%
Q4 FY2025Dec 28, 2025$45.80M-3.2%
Q3 FY2025Sep 28, 2025$41.50M-25.8%
Q2 FY2025Jun 29, 2025$45.70M-18.8%
Q1 FY2025Mar 30, 2025$53.20M-10.1%
Q4 FY2024Dec 29, 2024$47.30M-20.2%
Q3 FY2024Sep 29, 2024$55.90M-9.1%
Q2 FY2024Jun 30, 2024$56.30M-9.8%
Q1 FY2024Mar 31, 2024$59.20M-5.0%
Q4 FY2023Dec 31, 2023$59.30M-3.9%
Q3 FY2023Oct 1, 2023$61.50M-6.3%
Q2 FY2023Jul 2, 2023$62.40M+82.5%
Q1 FY2023Apr 2, 2023$62.30M+136.0%
Q4 FY2022Jan 1, 2023$61.70M+136.4%
Q3 FY2022Oct 2, 2022$65.60M+176.8%
Q2 FY2022Jul 3, 2022$34.20M+51.3%
Q1 FY2022Apr 3, 2022$26.40M–
Q4 FY2021Jan 2, 2022$26.10M–
Q3 FY2021Oct 3, 2021$23.70M–
Q2 FY2021Jul 4, 2021$22.60M–

More QuidelOrtho figures

See a number that looks wrong?